109 results
424B3
CRVO
CervoMed Inc
6 Jun 24
Prospectus supplement
6:03am
success, including having played major roles during the clinical development of five innovative drugs that are now on the market, and is an emerging … at McGill University.
Our Strategy
Our mission is to develop and commercialize innovative medicines that change the course of the disease
8-K
EX-99.2
CRVO
CervoMed Inc
7 Feb 24
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
4:06pm
efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products
8-K
EX-99.1
09a9fyktpgk4y qy4
7 Feb 24
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
4:06pm
8-K
EX-99.1
2yvfymglzmadc2xd5ici
5 Jan 24
CervoMed to Participate in the Emerging Growth Conference 66
4:05pm
8-K/A
EX-99.3
kag5vx0tqbg4anm7
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
PRRN14A
vf43b
6 Dec 22
Revised preliminary proxy statement filed by non-management
8:30am
DEFC14A
0r0j02
5 Dec 22
Proxy in contested solicitation
5:12pm
PRRN14A
2egmk 0ysccomh
2 Dec 22
Revised preliminary proxy statement filed by non-management
2:36pm
PRER14A
mpnrayengcnnh0hzone
28 Nov 22
Preliminary revised proxy
5:17pm
PREC14A
29cy3sh26lhu3i9kz
23 Nov 22
Preliminary proxy with contested solicitation
11:26am
PREC14A
8y9yymlwjgsy6fy
18 Nov 22
Preliminary proxy with contested solicitation
5:08pm
DFAN14A
l9cx9 5gwx
18 Nov 22
Additional proxy materials by non-management
11:02am
8-K
EX-99.1
7300sa37v79c4nl
16 Aug 22
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4:21pm
8-K
EX-99.1
6lo6w dxep3g7jh9
27 Jul 22
Other Events
7:30am